S&P Futures
4,145.50 +13.25 (+0.32%) Dow Futures
33,993.00 -155.00 (-0.45%) Nasdaq Futures
12,564.25 +150.00 (+1.21%) Russell 2000 Futures
1,965.20 -3.20 (-0.16%) Crude Oil
76.06 -0.35 (-0.46%) Gold
1,970.30 +27.50 (+1.42%)
(AMGN34.SA)
Chart Events
Performance Outlook
| Previous Close | 45.55 |
| Open | 0.00 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.00 - 0.00 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | 658.614B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 2.28 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AMGN34.SA
Related Research
- Motley Fool
Why Amgen Stock Wilted on Wednesday
The stock of veteran biotech Amgen (NASDAQ: AMGN) was looking a little tired on Wednesday. The company's shares fell more than 2% in price, "thanks" to fourth-quarter results that didn't put smiles on investors' faces. In contrast to gloomy Amgen, the S&P 500 index ticked up by slightly more than 1%.
- Investor's Business Daily
There's A Key Element Missing From Amgen's 2023 Outlook, Making Comparisons 'Messy'
Amgen issued an outlook that discounts its looming acquisition of Horizon Therapeutics. In response, Amgen stock skidded Wednesday morning.
- Reuters
FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high
U.S. patients will finally get access to cheaper versions of AbbVie Inc’s blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing. One sets a 5% discount to Humira’s monthly price of $6,922.
